Andrew Kosky

Genentech, a Member of the Roche Group

Andrew Kosky, Ph.D., is Senior Director and Head of the Technical Development Leaders in South San Francisco, where he oversees and directs all of the CMC development teams and strategies for the Genentech product portfolio. Andrew joined Genentech in 2009 and has served in a variety of positions of increasing responsibility in Pharma Technical Development, including functional leadership roles in formulation and purification departments, as Technical Leader for Perjeta, and leader of numerous cross-company initiatives and task forces. Since 2012, Andrew has overseen the CMC teams that drove the successful approval and launch of multiple new products and products versions including Perjeta, Kadcyla, Tecentriq, Ocrevus, Venclexta, Cotellic, Lucentis PFS, and Polivy.

Prior to Genentech, Andrew was at Amgen in Thousand Oaks, CA, where he was a leader in the Analytical and Formulation Development and a senior scientist and group leader for many years in the Pharmaceutics and Drug Delivery organization. Andrew began his career at Synergen Inc. (Boulder, Colorado) in 1991 as a researcher in the Formulation Development and Discovery Research departments. His research has focused characterization of protein degradation pathways and on the interdependence of protein covalent degradation (e.g., deamidation) and protein structure. Andrew holds a B.S. in Physical Science from Colorado State University and a Ph.D. in Pharmaceutical Science from the University of Colorado Health Sciences Center.